Sam Falsetti, PhD of Cambridge Biomarketing discusses some of the biotech and rare disease successes of 2017, including the emergence of RNA therapies with the approval of Exondys 51 for Duchenne muscular dystrophy, as well as gene and CAR-T therapies that have had significant FDA approvals in 2017.